Psychotropic Polypharmacy and Related Factors in Children and Adolescents
Open Access
- 22 August 2025
- journal article
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 22 (9) , 979-988
Abstract
We aimed to investigate the clinical characteristics of patients presenting to child and adolescent psychiatry outpatient clinics across different age groups, and to assess the prevalence of polypharmacy along with its associated factors within a clinical sample. A total of 569 patients with complete file data were included in the study. Psychiatric diagnoses were made by a clinician based on the diagnostic criteria stipulated in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. A detailed medical history was obtained for each patient, and their age, gender, education level, parents' age and education level, psychiatric diagnoses, and administered treatments were recorded for further analyses. Based on a review of the relationship between complaints at presentation and polypharmacy, irritability was more prevalent among polypharmacy users, while domestic problems were more prevalent in those who did not use polypharmacy. Based on our regression analysis; conduct disorder (CD) diagnosis (B=2.405, Exp [B]=11.079, p<0.001), age (B=0.127, Exp [B]=1.136, p=0.008), and any psychiatric comorbidity (B=4.761, Exp [B]=116.874, p<0.001) were the variables most frequently and significantly associated with polypharmacy independent of other variables. This study's results indicate that the presence of CD, age, and comorbid psychiatric diagnosis significantly increase the risk of polypharmacy. A better understanding of the factors that pave the way toward polypharmacy is critical to reduce unnecessary medication use in children and adolescents.Keywords
This publication has 30 references indexed in Scilit:
- Meta-analysis of Functional Neuroimaging of Major Depressive Disorder in YouthJAMA Psychiatry, 2015
- Provision of mental healthcare for children and adolescentsCurrent Opinion in Psychiatry, 2015
- Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and TolerabilityCurrent Psychiatry Reports, 2013
- Effects of antipsychotic polypharmacy on side‐effects and concurrent use of medications in schizophrenic outpatientsPsychiatry and Clinical Neurosciences, 2012
- Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patientsNeuropsychiatric Disease and Treatment, 2010
- Epidemiology of Speech and Language Impairment in a Nationally Representative Sample of 4- to 5-Year-Old ChildrenJournal of Speech, Language, and Hearing Research, 2009
- Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkableExpert Opinion on Drug Safety, 2007
- Comorbidity of internalizing disorders in children with oppositional defiant disorderEuropean Child & Adolescent Psychiatry, 2007
- Quality of Life in Children With Psychiatric Disorders: Self-, Parent, and Clinician ReportJournal of the American Academy of Child & Adolescent Psychiatry, 2004
- Attention-deficit hyperactivity disorder and hyperkinetic disorderThe Lancet, 1998